凝集素Griffithsin抗冠状病毒作用的研究进展  

Progress on Lectin Griffithsin in Anti-coronavirus Infection

作　　者：梅朋 黄晓紫 周炫汝 崔红杰 吴异健[3] 刘萍[1,2] MEI Peng;HUANG Xiao-zi;ZHOU Xuan-ru;CUI Hong-jie;WU Yi-jian;LIU Ping(Key Laboratory of Animal Pathogen Infection and Immunology of Fujian Province,Fujian Agriculture and Forestry University,Fuzhou,Fujian,350002,China;Key Laboratory of Fujian-Taiwan Animal Pathogen Biology,Fujian Agriculture and Forestry University,Fuzhou,Fujian,350002,China;College of Animal Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,350002,China)

机构地区：[1]福建农林大学福建省畜禽病原感染与免疫学重点实验室,福建福州350002 [2]福建农林大学闽台动物病原生物学福建省高校重点实验室,福建福州350002 [3]福建农林大学动物科学学院,福建福州350002

出　　处：《动物医学进展》2025年第6期97-104,共8页Progress In Veterinary Medicine

基　　金：福建农林大学科技创新专项基金项目(CXZX2020056A);福建省自然科学基金项目(2021J01082)。

摘　　要：冠状病毒(CoVs)因其对人类和动物健康造成的严重威胁而广受关注。凝集素格瑞弗森(GRFT)在冠状病毒感染防控中显示出优良的抗病毒作用,已成为研究热点。论文重点剖析了冠状病毒囊膜蛋白的糖基化修饰特征、GRFT结构及其抗病毒机制,总结了GRFT抗人类和动物冠状病毒的研究进展,并分析GRFT作为潜在抗冠状病毒药物的优势与面临的挑战。未来可通过多种抗病毒成分联合应用和优化GRFT递送系统,进一步提升其在人类临床和兽医领域中的应用潜力。此外,结合基因编辑技术,有望降低GRFT生产成本并提高其治疗效果,为防控人类和动物冠状病毒性疫病提供新的策略。Coronaviruses(CoVs)have attracted widespread attention due to their serious threat to human and animal health.Griffithsin(GRFT)has become a scientific hotspot due to its antiviral properties in combating coronavirus infection.This review focused on the glycosylation of coronavirus envelope proteins,the structural characteristics of GRFT and its antiviral mechanism,summarized the research progress of GRFT on human and animal coronaviruses,and analyzed the advantages and challenges of GRFT as a potential anti-coronavirus drug.In the future,the combination of multiple antiviral components and the optimization of GRFT delivery system will further enhance its application potential in human clinic and veterinary fields.In addition,combined with gene editing technology,it is expected to reduce the production cost and improve the therapeutic effect of GRFT,providing new strategies and methods for global prevention and control of coronavirus diseases.

关 键 词：格瑞弗森 冠状病毒 刺突蛋白 糖基化修饰 抗病毒感染 

分 类 号：S852.659.6[农业科学—基础兽医学] S852.45[农业科学—兽医学]